| ID Source | ID |
|---|---|
| PubMed CID | 146388 |
| SCHEMBL ID | 10704664 |
| MeSH ID | M0173482 |
| Synonym |
|---|
| ro 15-5458 |
| 9(10h)-acridinone, 10-(2-(diethylamino)ethyl)-, (4,5-dihydro-2-thiazolyl)hydrazone |
| 10-(2-(diethylamino)ethyl)-9(10h)-acridinone(thiazolidin-2-ylidene)hydrazone |
| 10-(2-(diethylamino)ethyl)-9(10h)-acridinone (4,5-dihydro-2-thiazolyl)hydrazone |
| ro15-5458 |
| ro-15-5458 |
| 92928-47-7 |
| SCHEMBL10704664 |
| DTXSID30239205 |
| 10-[2-(diethylamino)ethyl]-9-acridanone-(thiazolidin-2-ylidene) hydrazone |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters were measured in naive mice." | ( Efficacy, metabolism and pharmacokinetics of Ro 15-5458, a forgotten schistosomicidal 9-acridanone hydrazone. Caffrey, CR; Charman, SA; Dong, Y; El-Sakkary, N; Gangoiti, J; Häberli, C; Huang, J; Keiser, J; Momper, JD; Probst, A; Siegel, D; Skinner, DE; Ta, AP; Vennerstrom, JL; Vigneron, S, 2020) | 0.82 |
The effect of Ro 15-5458 on the steady-state RNA levels of Schistosoma mansoni was studied after dosing the host with 15 mg kg-1 and retrieving parasites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of Ro 15-5458 (10-2-(diethylamino)ethyl-9-acridanone(2-thiazolin- 2-yl)hydrazone) on the steady-state RNA levels of Schistosoma mansoni was studied after dosing the host with 15 mg kg-1 and retrieving parasites." | ( The schistosomicidal compound Ro 15-5458 causes a reduction in the RNA content of Schistosoma mansoni. Bennett, JL; Eshete, F, 1991) | 0.93 |
| "We evaluated a variety of biochemical parameters in Schistosoma mansoni isolated from mice up to 4 days after dosing with 15 mg/kg Ro 15-5458." | ( Schistosoma mansoni: biochemical characteristics of the antischistosomal effects of Ro 15-5458. Bennett, JL; Eshete, F, 1990) | 0.71 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.65) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||